Sean R. Corcoran
YOU?
Author Swipe
View article: Supplementary Tables S1-S12 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas
Supplementary Tables S1-S12 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas Open
Table S1. Brunello library sgRNA normalized read counts of IRF4 sorted CRISPR screens. Table S2. Segregation score of IRF4 sorted CRISPR screens. Table S3. Glycoproteomics in STT3A or STT3B KO cells. Table S4. Brunello sgRNA Library Normal…
View article: Supplementary Figures S1-10 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas
Supplementary Figures S1-10 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas Open
Supplemental Figure 1. IRF4-GFP knock-in reporter cell lines. Supplemental Figure 2. IRF4-GFP CRISPR screen in adult T-cell lymphoma and screen controls. Supplemental Figure 3. The OST is essential for DLBCL. Supplemental Figure 4. The rol…
View article: Supplementary Tables S1-S12 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas
Supplementary Tables S1-S12 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas Open
Table S1. Brunello library sgRNA normalized read counts of IRF4 sorted CRISPR screens. Table S2. Segregation score of IRF4 sorted CRISPR screens. Table S3. Glycoproteomics in STT3A or STT3B KO cells. Table S4. Brunello sgRNA Library Normal…
View article: Supplementary Figures S1-10 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas
Supplementary Figures S1-10 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas Open
Supplemental Figure 1. IRF4-GFP knock-in reporter cell lines. Supplemental Figure 2. IRF4-GFP CRISPR screen in adult T-cell lymphoma and screen controls. Supplemental Figure 3. The OST is essential for DLBCL. Supplemental Figure 4. The rol…
View article: Supplementary Figure S14 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S14 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
Inhibition of neddylation increases expression of BCR subunits
View article: Supplementary Figure S9 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S9 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
Mutation of CD79A and CD79B glycosylated residues does not alter sensitivity to MMAE
View article: Supplementary Table 1 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Table 1 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
CRISPR Screen Scores
View article: Supplementary Figure S10 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S10 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
KLHL6 loss does not score as a negative regulator of surface CD79B or Pola-V sensitivity in CRISPR screens of ABC DLBCL cell lines and KLHL6 loss does not sensitize to MMAE
View article: Supplementary Figure S2 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S2 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
Knockout of SLC35A1, SLC35A2, and ST6GAL1 decreases surface a2,6-linked sialic acid.
View article: Supplementary Table 3 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Table 3 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
KLHL6 proteomics
View article: Supplementary Table 2 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Table 2 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
Glycoproteomics
View article: Supplementary Figure S9 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S9 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
Mutation of CD79A and CD79B glycosylated residues does not alter sensitivity to MMAE
View article: Supplementary Figure S13 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S13 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
DLBCL mutations targeting the CD79B intracellular domain and their effect on surface BCR levels
View article: Supplementary Figure S11 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S11 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
Knockout of the E3 ligase KLHL6 results in increased cell surface CD79B in a human model of GCB DLBCL
View article: Supplementary Figure S4 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S4 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
SLC35A2 targeted degradation by dTag modification synergizes with Pola-V.
View article: Supplementary Figure S5 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S5 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
CD79B immunohistochemistry is not predictive of Pola-V sensitivity
View article: Supplementary Table 1 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Table 1 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
CRISPR Screen Scores
View article: Supplementary Figure S14 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S14 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
Inhibition of neddylation increases expression of BCR subunits
View article: Supplementary Figure S11 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S11 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
Knockout of the E3 ligase KLHL6 results in increased cell surface CD79B in a human model of GCB DLBCL
View article: Supplementary Figure S12 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S12 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
Knockout of Klhl6 in mouse germinal center B cells increases surface BCR expression
View article: Supplementary Figure S6 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S6 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
Sialidase treatment reduces surface α2,6-linked sialic acid
View article: Supplementary Figure S3 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S3 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
Small-molecule sialyltransferase inhibition synergizes with Pola-V in ABC and GCB DLBCL
View article: Supplementary Figure S4 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S4 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
SLC35A2 targeted degradation by dTag modification synergizes with Pola-V.
View article: Supplementary Figure S8 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S8 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
Knock-In mutations to specific N-linked glycosylation sites results in higher CD79B but not immunoglobulin MFI by flow cytometry
View article: Supplementary Figure S8 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S8 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
Knock-In mutations to specific N-linked glycosylation sites results in higher CD79B but not immunoglobulin MFI by flow cytometry
View article: Supplementary Figure S3 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S3 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
Small-molecule sialyltransferase inhibition synergizes with Pola-V in ABC and GCB DLBCL
View article: Data from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Data from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
Polatuzumab vedotin (Pola-V) is an antibody–drug conjugate directed to the CD79B subunit of the B-cell receptor (BCR). When combined with conventional immunochemotherapy, Pola-V improves outcomes in diffuse large B-cell lymphoma (DLBCL). T…
View article: Supplementary Figure S13 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S13 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
DLBCL mutations targeting the CD79B intracellular domain and their effect on surface BCR levels
View article: Supplementary Figure S15 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S15 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
CD79B is degraded in a lysosomal, not proteasomal manner
View article: Supplementary Figure S7 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S7 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
Sialidase treatment does not increase binding of other therapeutic antibodies